Putnam Retirement Advantage 2065 Fund Class R4 (PCKHX) News

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine

SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to...

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial...

Les nouvelles données portant sur AJOVY® (fremanezumab) dans la prévention de la migraine remettent en question les pauses thérapeutiques

Les résultats de la 4e analyse intermédiaire réalisée dans le cadre de l’étude PEARL sur la prévention de la migraine en situation réelle ont...

Neue Daten zu AJOVY® (Fremanezumab) zur Migräneprävention stellen Behandlungspausen in Frage

Vierte Zwischenanalyse der PEARL-Studie zur Migräneprävention wird auf dem 10. Kongress des European Association of Neurology (EAN) in Helsinki...

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in...

Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the...

Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States

Generic Victoza® is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market. This launch...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities